Navigation Links
GlycoCheck Announces Partnership in the United States with Vascular Health Sciences
Date:1/16/2013

Maastricht, The Netherlands (PRWEB) January 16, 2013

GlycoCheck B.V., a leading provider of imaging and measurement software of the endothelial glycocalyx layer, today announced a reseller partnership with U.S.-based Vascular Health Sciences.

Vascular Health Sciences will exclusively distribute GlycoCheck Vascular Health Monitor (VHM) in the United States. GlycoCheck VHM is a complete imaging solution for screening patients’ perfused boundary layer inside the blood vessels. The new technology measures and monitors changes in the glycocalyx layer non-invasively, accurately and in real time.

“We are pleased that Vascular Health Sciences has made a commitment to offer our GlycoCheck VHM solution to their customers throughout the United States,” said GlycoCheck CEO Pieter Goedhart.

GlycoCheck recently debuted in U.S. markets when Vascular Health Sciences attended the Age Management Medicine and Holistic Primary Care Conferences when doctors offered very favorable reviews of both GlycoCheck and Vascular Health Sciences’ all-natural artery health supplement, Arterosil.

“GlycoCheck provides a unique and novel technology to assess artery health in real time,” said Vascular Health Sciences Co-Founder and CEO Bob Long. “The more trials we conduct, both in the clinical setting and in a non-controlled conference setting, the more positive evidence we observe that proves Arterosil and Arterosil HP work. We’re thrilled to offer the benefits of this new technology to Health Care Practitioners and their patients.”

About GlycoCheck
GlycoCheck is a leading provider of imaging solutions based on an innovative measurement system of the Glycocalyx layer. GlycoCheck solutions facilitate the accurate, reliable and non-invasive selection, detection & monitoring of patients in primary care, intensive care, cardiology and internal medicine. To learn more about GlycoCheck, visit GlycoCheck.com.

About Vascular Health Sciences
Founded in 2010, Vascular Health Sciences explores technologies, develops products and disseminates information to increase awareness and promote the proper care of the endothelial glycocalyx. Vascular Health Sciences is committed to increasing awareness of the glycocalyx and its role in vascular health, and to providing products supporting the care of this essential system. For more information, visit VascularHealthSciences.com.

About Arterosil
Arterosil, a product of Vascular Health Sciences, is an all-natural health supplement focused on vascular health. It’s the only health supplement scientifically proven to support and maintain the glycocalyx, – the micro-thin gel-like lining that protects the heart, veins and arteries.* It’s also scientifically proven to optimize capillary architecture and increase micro-circulatory functionality.* Arterosil is available at Arterosil.com, where monthly auto-ship options are available with free shipping, as well as 30-, 90- and 365-day supplies. Learn more at Arterosil.com, or find Arterosil on Facebook and follow Arterosil on Twitter.

*FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Read the full story at http://www.prweb.com/releases/arterosil/glycocheck/prweb10316378.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. This ... products engineered to radically streamline culture processes, minimize processing time, significantly decrease ...
(Date:12/8/2016)... Dec. 8, 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: ... develops and plans to commercialize innovative therapeutics for ... common stock were approved for trading on the ... on the OTCQX, effective today, under the ticker ... OTCQX market, companies must meet high financial standards, ...
(Date:12/7/2016)... ... 07, 2016 , ... ACEA Biosciences, Inc. presented today updated ... trial for its lead drug candidate, AC0010, at the World Conference on Lung ... determine the safety, antitumor activity, and recommended phase II dosage of AC0010 in ...
(Date:12/7/2016)... Dec. 7, 2016 /PRNewswire/ - Zenith Capital Corp. ("Zenith" or the ... be presented at the Company,s Annual and Special Meeting. ... will take place on Thursday, December 15, 2016 at ... (Room EC1040), 4825 Mount Royal Gate SW, ... notice of meeting and management information circular, containing the matters ...
Breaking Biology Technology:
(Date:12/2/2016)... Dec. 1, 2016   SoftServe , a ... BioLock , an electrocardiogram (ECG) biosensor analysis system ... key IoT asset. The smart system ensures device-to-device ... steering wheel and mobile devices to easily ,recognize, ... As vehicle technology advances, so too must ...
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
(Date:11/22/2016)... According to the new market research report "Biometric ... Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, ... is expected to grow from USD 10.74 Billion in 2015 to reach ... and 2022. Continue Reading ... ...
Breaking Biology News(10 mins):